RxDoctor Payments Data

John Ellsworth, MD

Urology · St George, UTNPI 1083619043

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,510 of the $5,047 with a category attached, or 89.3%. Boston Scientific accounts for 80.5% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $1,861 and has fallen 81.7% since, to $341 in 2025.

$5,047in general payments, 2019–2025

Across 102 payments — averaging $49.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • AbbVie$331
  • Procept Biorobotics Corporation$134
  • Dendreon Pharmaceuticals LLC$120
  • Sumitomo Pharma America, Inc.$113
  • Axonics, Inc.$74
  • plus $212 from 8 others

What the payments were for

  • Travel & lodging$53811%
  • Food & beverage$4,51089%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,047 in reported general payments places this provider in the 55th percentile of 96 urology providers in Utah.

See all urology providers in Utah

Medicare billing

Part B allowed, 2024
$507,144
Medicare patients
1,049
Services billed
41,768

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron66$73,838
Tamsulosin Hcl1,001$28,316
GemtesaVibegron31$25,154
Finasteride472$7,314
Solifenacin Succinate221$6,902
Silodosin72$5,498
Estradiol72$4,228
Tadalafil36$3,443
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst91$3,009
Ciprofloxacin Hcl328$2,409
Testosterone Cypionate51$2,313
Alfuzosin Hcl ErAlfuzosin Hcl94$2,264
Testosterone12$2,208
Dutasteride43$2,042
NitrofurantoinNitrofurantoin Macrocrystal35$1,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$13$73,83866 claims
Sumitomo Pharma America, Inc.Gemtesa$113$25,15431 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 96 urology providers in Utah.

Other urology in St George

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →